SS31 10mg + MOTS-C 10mg + NAD+ 200mg Blend

The three compounds operate at distinct but interconnected points in mitochondrial biology. SS-31 supports the membrane environment in which oxidative phosphorylation occurs. MOTS-c provides upstream signalling input affecting energy substrate use. NAD+ serves as the required coenzyme for the redox reactions driving ATP synthesis and downstream sirtuin signalling. The composition is designed for research into integrated approaches to mitochondrial function across structural, signalling, and substrate-level inputs simultaneously.

SS-31 has progressed through clinical trials in specific therapeutic contexts. NAD+ and its precursors (NMN, NR) have been the subject of a growing body of human studies. MOTS-c remains earlier in its research trajectory. The three-compound combination itself hasn't been subject to large-scale clinical investigation

Published studies on the individual compounds have explored:

Mitochondrial efficiency: Improved ATP output and reduced oxidative stress markers across cell and animal models.
Metabolic regulation: Improvements in glucose handling, insulin sensitivity, and lipid metabolism, primarily in animal models.
Skeletal muscle function: Enhanced exercise capacity and mitochondrial biogenesis in animal models, with relevance to "exercise mimetic" research.
Cardiac research: SS-31 has been studied in heart failure and ischemic injury models.
Ageing-related research: All three compounds have been examined for effects on age-associated decline, with NAD+ research particularly active in this space.

Combined-administration data is limited.